title: Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy.
abstract: BACKGROUND
  Autopsy studies report a reservoir of small, occult, undiagnosed breast cancers in up to 15.6% of women dying from unrelated causes. The effective doubling times (EDT) of these occult neoplasms range from 70 to 350 days and mammographic detection threshold diameters from 0.88 to 1.66 cm. Modeling of the biologic behavior of these occult tumors facilitates interpretation of tamoxifen breast cancer prevention and menopausal hormone therapy studies.
  
  
  METHODS
  We used iterative and mathematical techniques to develop a model of occult tumor growth (OTG) whose parameters included prevalence, EDT, and detection threshold. The model was validated by comparing predicted with observed incidence of breast cancer in several populations.
  
  
  RESULTS
  Iterative analysis identified a 200-day EDT, 7% prevalence and 1.16 cm detection threshold as optimal parameters for an OTG model as judged by comparison with Surveillance Epidemiology and End Results (SEER) population incidence rates in the United States. We validated the model by comparing predicted incidence rates with those observed in five separate population databases, in three long-term contralateral breast cancer detection studies, and with data from a computer-simulated tumor growth (CSTG) model. Our model strongly suggests that breast cancer prevention with anti-estrogens or aromatase inhibitors represents early treatment not prevention. In addition, menopausal hormone therapy does not primarily induce de novo tumors but promotes the growth of occult lesions.
  
  
  CONCLUSIONS
  Our OGTG model suggests that occult, undiagnosed tumors are prevalent, grow slowly, and are the biologic targets of anti-estrogen therapy for prevention and hormone therapy for menopausal women.
authors.affiliation: Department of Internal Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA 22908, USA. rjs5y@virginia.edu
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Santen
authors.forename: Wei
authors.initials: W
authors.lastname: Yue
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Heitjan
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control*; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D015994:Incidence; D008593:Menopause; D008875:Middle Aged; D015233:Models, Statistical; D009376:Neoplasms, Hormone-Dependent / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control*; D013629:Tamoxifen / Q000008:administration & dosage; D014481:United States / Q000453:epidemiology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen